TFCP2

Transcription factor CP2 (TFCP2), also known as Late SV40 Factor (LSF), is a sequence-specific DNA-binding transcription factor that regulates erythroid gene expression and mediates transcriptional switching of globin gene promoters through promoter-binding complexes involved in developmental gene control^[1][2]. Mechanistically, TFCP2 belongs to the TFCP2/TFCP2L1/UBP1 transcription factor subfamily and contains conserved DNA-binding and dimerization domains that support transcriptional regulation across diverse cellular programs^[3][4]. Beyond hematopoietic regulation, TFCP2 controls cellular proliferation, differentiation, angiogenesis, and inflammatory gene expression through transcriptional activation of multiple cellular promoters and signaling-associated targets^[1][5]. In disease contexts, aberrant TFCP2 activity has been linked to hepatocellular carcinoma, where it functions as an oncogenic transcription factor, and recurrent FUS-TFCP2 or EWSR1-TFCP2 fusion events define an aggressive subgroup of spindle cell and epithelioid rhabdomyosarcomas characterized by frequent ALK upregulation and poor clinical outcomes^[6][7]. Compared with related isoforms TFCP2L1 and UBP1, TFCP2 exhibits distinct cancer-associated functions and has emerged as the most extensively characterized member of this transcription factor subfamily in tumor biology^[8]. For experimental applications, the small-molecule inhibitor FQI1 suppresses TFCP2 DNA-binding activity and has been widely used to investigate TFCP2-dependent transcriptional programs and oncogenic signaling mechanisms in cancer models^[6].